Mental disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:20:37 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Mental disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A Study of Donanemab in People With Early Symptomatic Alzheimer’s Disease https://clinicaltrials.eu/trial/a-study-of-donanemab-in-people-with-early-symptomatic-alzheimers-disease/ Wed, 29 Apr 2026 15:07:45 +0000 https://clinicaltrials.eu/trial/a-study-of-donanemab-in-people-with-early-symptomatic-alzheimers-disease/ This study is looking at Alzheimer’s disease in people who are in the early stages of the condition. Alzheimer’s disease is a brain disorder that gradually affects memory, thinking, and the ability to carry out daily activities. The study will test a medication called donanemab (also known by its code name LY3002813), which is an antibody designed to target a protein called amyloid beta that builds up in the brains of people with Alzheimer’s disease. Some participants will receive donanemab while others will receive placebo. The study will also use special imaging substances called florbetapir (code name LY3078786) and flortaucipir (code name LY3191748) that help doctors see protein deposits in the brain through scanning procedures. Sodium chloride will be used as part of the treatment process.

The purpose of this study is to see whether donanemab can slow down the worsening of symptoms compared to placebo in people with early symptomatic Alzheimer’s disease. The study will measure changes in memory, thinking abilities, and daily functioning over time to determine if the treatment is effective.

During the study, participants will receive the study medication through an infusion into a vein. The treatment will continue for a period of time while doctors monitor how well participants are doing with their memory and daily activities. Participants will need to have a study partner who knows them well and can provide information about any changes in their condition. The study will use brain scans to check for the presence of certain proteins that are associated with Alzheimer’s disease. These scans help doctors understand the extent of the disease and monitor any changes during the study.

]]> Study on Rituximab for Patients with Mental Disorders and Autoimmunity https://clinicaltrials.eu/trial/study-on-rituximab-for-patients-with-mental-disorders-and-autoimmunity/ Wed, 29 Apr 2026 14:22:43 +0000 https://clinicaltrials.eu/trial/study-on-rituximab-for-patients-with-mental-disorders-and-autoimmunity/ This clinical trial is focused on studying certain mental disorders that are believed to be linked to the immune system. The treatment being tested is called rituximab, which is a type of medication that helps to modify the immune system. Rituximab is given as an infusion, which means it is administered directly into the bloodstream through a vein. The purpose of this study is to evaluate how effective this treatment is when added to the usual psychiatric care that patients are already receiving.

The study will involve participants who have been diagnosed with mental disorders and have shown signs of an immune system problem. Participants will receive either the rituximab treatment or a placebo, in addition to their regular psychiatric care. The study will last for several months, and during this time, participants will be monitored to see if their psychiatric symptoms improve. The main goal is to see if there is a reduction in symptoms after three months of treatment.

Throughout the study, participants will undergo various assessments to measure their mental health and overall functioning. These assessments will help researchers understand the impact of rituximab on mental disorders and whether it can be a beneficial addition to standard treatments. The study will also track any side effects or adverse events that occur during the trial to ensure the safety of the participants.

]]>